MaxCyte®

Result of AGM
November 2, 2020

Released : November 02, 2020 15:52

Result of AGM

Gaithersburg, Maryland - 02 November 2020: MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, announces that at its Annual General Meeting held on 30th October 2020, all resolutions were duly passed.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

###

Contacts:

MaxCyte Inc.	+1 301-944-1660
Doug Doerfler, Chief Executive Officer	
Amanda Murphy, Chief Financial Officer	

Nominated Adviser and Joint Corporate Broker
Panmure Gordon   +44 (0)20 7886 2500
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden

Joint Corporate Broker
Numis Securities Limited   +44 (0)20 7260 1000
James Black
Duncan Monteith

Financial PR Adviser   +44 (0)203 709 5700
Consilium Strategic Communications   maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh

END

RAGBUBDBGUGDGGD